Related Experiment Videos

Cardiac troponin I release correlates with myocardial infarction size

J Mair1, I Wagner, B Morass

  • 1Institut für Medizinische Chemie & Biochemie, Universität Innsbruck, Austria.

European Journal of Clinical Chemistry and Clinical Biochemistry : Journal of the Forum of European Clinical Chemistry Societies
|November 1, 1995
PubMed

Insights

Cardiac troponin I levels correlate with myocardial infarct size in patients receiving thrombolytic therapy. Troponin I remains elevated longer than creatine kinase MB, offering a more prolonged indicator of cardiac damage.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Nuclear Medicine

Background:

  • Acute myocardial infarction (AMI) diagnosis relies on cardiac biomarkers.
  • Cardiac troponin I (cTnI) and creatine kinase MB (CK-MB) are key markers.
  • Assessing infarct size is crucial for patient prognosis.

Purpose of the Study:

  • To compare cTnI and CK-MB levels with infarct size estimates.
  • To evaluate the correlation between cTnI release and myocardial scar.
  • To determine the diagnostic utility of cTnI in Q-wave AMI.

Main Methods:

  • Serial blood sampling for cTnI, CK, and CK-MB in 15 AMI patients.
  • Thrombolytic therapy administered to all patients.
  • Myocardial scar quantified using SPECT with Tc-sestamibi, compared with cTnI and CK-MB levels.

Main Results:

  • cTnI and CK-MB peaked in parallel, with strong correlation (r=0.76).
  • cTnI remained elevated longer than CK-MB, detectable up to day 4.
  • Significant correlations found between Tc-sestamibi defect size and cTnI (r=0.53) and CK-MB (r=0.64).

Conclusions:

  • Cardiac troponin I release is correlated with infarct size in AMI.
  • cTnI offers a more sustained biomarker profile compared to CK-MB.
  • SPECT Tc-sestamibi defect size is a reliable indicator of infarct size, correlating with cTnI release.

Related Concept Videos